Shares of Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) skyrocketed 82% in U.S. trading on Friday, reaching $0.8299 after peaking at $1.11 earlier in the session. The dramatic surge followed the company's announcement of a $2.61 million private placement and warrant inducement deal aimed at bolstering its contract development and manufacturing organization (CDMO) expansion and immunotherapy pipeline.
Private Placement Details
Scinai secured the financing through the sale of 5,208,333 American Depositary Shares (ADSs) at $0.48 per share to an institutional life-sciences backer and a mix of new and returning investors. The deal also includes Series A warrants exercisable at $0.48 for two years and Series B warrants exercisable at $0.55 for five years. Additionally, the company entered into a warrant inducement agreement with an institutional investor, who immediately exercised warrants for 229,310 ADSs at $0.48 each, receiving new unregistered warrants covering 458,621 ADSs at $0.55 per ADS. The transactions are expected to close around April 27, subject to standard conditions.
Financial Context and Going-Concern Warning
Scinai reported $1.6 million in cash and cash equivalents as of December 31, with its annual financial statements including a going-concern warning. The company noted that it does not have sufficient funds to cover a full year of planned operations from the date of its financial statement, and CDMO revenue has yet to fill the gap. The company posted 2025 revenue of $1.3 million, up from $0.7 million the prior year, but still recorded a net loss of $8.3 million.
Strategic Shift to CDMO
The funding will support Scinai's strategic pivot toward its CDMO business, which handles drug development and production for clients. In April, the company carved out its CDMO operations into a newly formed subsidiary, Scinai Biopharma Services Ltd., while streamlining its R&D unit. CEO Amir Reichman described the restructuring as a way to "align our structure with our strategy." The CDMO platform now consists of three components: its biologics and aseptic plant in Jerusalem, the newly acquired Yavne site for small molecules and APIs from Recipharm Israel, and a commercial deal with Recipharm's global network. Scinai is targeting approximately $5 million in CDMO revenue by 2026.
Market Context and Risks
Scinai's move into the CDMO sector places it in competition with industry giants like Lonza, which expects core CDMO sales to grow 11% to 12% in 2026. However, the company faces significant risks, including potential shareholder dilution from warrant exercises and the need to maintain Nasdaq's minimum bid price of $1.00 for 10 consecutive sessions before September 8. If Scinai cannot secure additional funds, it may be forced to scale back or cease operations. A.G.P./Alliance Global Partners served as the sole financial adviser on the deal.
Scinai's ability to convert customer programs into sustainable CDMO revenue while funding its early-stage immunotherapy projects—including PC111 and NanoAbs programs from Max Planck and PinCell—will be critical. The company must execute without over-relying on new equity financing.
